Published in Oncotarget on September 06, 2016
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 21.59
SH2 domains recognize specific phosphopeptide sequences. Cell (1993) 17.28
Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res (2006) 7.91
Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med (2006) 5.92
CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell (2009) 5.22
Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol (2004) 5.10
Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol (2003) 4.66
Self-renewal as a therapeutic target in human colorectal cancer. Nat Med (2013) 4.20
Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity (2004) 3.25
Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J Clin Invest (2010) 2.96
Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell (2009) 2.60
Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood (2001) 2.54
Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica (2012) 1.81
The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood (2007) 1.81
Linking the Rb and polycomb pathways. Mol Cell (2001) 1.76
TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell (2010) 1.64
Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression. J Immunol (1997) 1.52
Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene (2010) 1.45
Inhibitory receptors, ITIM sequences and phosphatases. Curr Opin Immunol (1997) 1.41
Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis. Blood (2005) 1.36
C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res (2004) 1.32
Polycomb-group proteins in hematopoietic stem cell regulation and hematopoietic neoplasms. Leukemia (2012) 1.07
Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica (2009) 1.03
Role of the polycomb group gene BMI1 in normal and leukemic hematopoietic stem and progenitor cells. Curr Opin Hematol (2010) 1.02
CD44 in hematological neoplasias. Ann Hematol (2011) 0.96
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treat Rev (2007) 0.93
TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells. Int J Hematol (2013) 0.92
YXXM motifs in the PDGF-beta receptor serve dual roles as phosphoinositide 3-kinase binding motifs and tyrosine-based endocytic sorting signals. J Biol Chem (2003) 0.92
A TIM-3/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression. Cell Stem Cell (2015) 0.91
CD34 expression in native human acute myelogenous leukemia blasts: differences in CD34 membrane molecule expression are associated with different gene expression profiles. Cytometry B Clin Cytom (2005) 0.89
Targeting self-renewal pathways in myeloid malignancies. Cell Commun Signal (2013) 0.87
Identification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia. World J Stem Cells (2014) 0.85
[Cytotoxicity of homoharringtonine on leukemic stem-like cells in AML cell line KG-1]. Zhejiang Da Xue Xue Bao Yi Xue Ban (2012) 0.83
The clinical significance of CD34 expression in response to therapy of patients with acute myeloid leukemia: an overview of 2483 patients from 22 studies. Cancer (2000) 0.80
[Expression and clinical significance of Bmi-1 protein in bladder cancer]. Ai Zheng (2008) 0.78
Role of polycomb group proteins in the DNA damage response--a reassessment. PLoS One (2014) 0.77
Phospho-MEK1/2 and uPAR Expression Determine Sensitivity of AML Blasts to a Urokinase-Activated Anthrax Lethal Toxin (PrAgU2/LF). Transl Oncol (2015) 0.77
Anti-metastasis efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight heparin in surgical pancreatic cancer models. Int J Oncol (2014) 0.77
Downregulation of Bmi1 in breast cancer stem cells suppresses tumor growth and proliferation. Oncotarget (2017) 0.77
Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin. Cancer Lett (2014) 0.76
Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac. Int J Nanomedicine (2017) 0.75
Anti-CD24 nano-targeted delivery of docetaxel for the treatment of prostate cancer. Nanomedicine (2016) 0.75